Total Payments
$596,383
2024 Payments
$29,560
Companies
35
Transactions
1,145
Medicare Patients
3,385
Medicare Billing
$878,297
Payment Breakdown by Category
Other$544,918 (91.4%)
Travel$27,441 (4.6%)
Food & Beverage$17,378 (2.9%)
Consulting$6,425 (1.1%)
Education$142.98 (0.0%)
Gifts$77.85 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $529,618 | 289 | 88.8% |
| Travel and Lodging | $27,441 | 210 | 4.6% |
| Food and Beverage | $17,378 | 623 | 2.9% |
| Honoraria | $15,300 | 7 | 2.6% |
| Consulting Fee | $6,425 | 3 | 1.1% |
| Education | $142.98 | 10 | 0.0% |
| Gift | $77.85 | 3 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $230,463 | 393 | $0 (2020) |
| ABBVIE INC. | $227,484 | 320 | $0 (2024) |
| Alkermes, Inc. | $65,617 | 93 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $42,961 | 103 | $0 (2023) |
| Tris Pharma Inc | $16,446 | 21 | $0 (2024) |
| Vanda Pharmaceuticals Inc. | $7,424 | 14 | $0 (2024) |
| ITI, Inc. | $1,317 | 11 | $0 (2023) |
| Jazz Pharmaceuticals Inc. | $800.00 | 1 | $0 (2020) |
| Sunovion Pharmaceuticals Inc. | $666.24 | 42 | $0 (2021) |
| Neurocrine Biosciences, Inc. | $634.02 | 22 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $29,560 | 59 | ABBVIE INC. ($17,422) |
| 2023 | $104,590 | 175 | ABBVIE INC. ($94,318) |
| 2022 | $85,149 | 132 | ABBVIE INC. ($78,888) |
| 2021 | $54,645 | 114 | AbbVie Inc. ($36,857) |
| 2020 | $49,727 | 88 | Allergan, Inc. ($35,777) |
| 2019 | $105,176 | 180 | Allergan Inc. ($54,685) |
| 2018 | $74,303 | 181 | Allergan Inc. ($66,732) |
| 2017 | $93,233 | 216 | Allergan Inc. ($73,268) |
All Payment Transactions
1,145 individual payment records from CMS Open Payments — Page 1 of 46
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/26/2024 | Tris Pharma Inc | Dyanavel XR (Drug), Quillivant, Quillichew ER | Honoraria | Cash or cash equivalent | $3,000.00 | General |
| Category: ADHD | ||||||
| 11/26/2024 | Tris Pharma Inc | Dyanavel XR (Drug), Quillivant, Quillichew ER | Travel and Lodging | In-kind items and services | $294.80 | General |
| Category: ADHD | ||||||
| 11/25/2024 | Bausch Health US, LLC | APLENZIN (Drug), WELLBUTRIN | Food and Beverage | In-kind items and services | $18.94 | General |
| Category: Neurology | ||||||
| 11/20/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.43 | General |
| Category: NEUROSCIENCE | ||||||
| 11/11/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.15 | General |
| Category: NEUROSCIENCE | ||||||
| 11/07/2024 | Tris Pharma Inc | Dyanavel XR (Drug), Quillivant, Quillichew ER | Food and Beverage | In-kind items and services | $110.73 | General |
| Category: ADHD | ||||||
| 11/06/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $1.58 | General |
| Category: NEUROSCIENCE | ||||||
| 10/25/2024 | ABBVIE INC. | VRAYLAR (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,250.00 | General |
| Category: NEUROSCIENCE | ||||||
| 10/23/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $27.16 | General |
| Category: NEUROSCIENCE | ||||||
| 10/23/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.34 | General |
| Category: NEUROSCIENCE | ||||||
| 10/08/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $99.96 | General |
| Category: NEUROSCIENCE | ||||||
| 09/24/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.02 | General |
| Category: NEUROSCIENCE | ||||||
| 09/12/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: SCHIZOPHRENIA | ||||||
| 09/12/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| Category: SCHIZOPHRENIA | ||||||
| 09/12/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Travel and Lodging | Cash or cash equivalent | $6.70 | General |
| Category: SCHIZOPHRENIA | ||||||
| 08/28/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $101.33 | General |
| Category: Neuropsychiatry | ||||||
| 08/28/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $7.78 | General |
| Category: NEUROSCIENCE | ||||||
| 08/21/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $26.66 | General |
| Category: Neuropsychiatry | ||||||
| 08/15/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.31 | General |
| Category: NEUROSCIENCE | ||||||
| 08/07/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $19.49 | General |
| Category: Neuropsychiatry | ||||||
| 08/02/2024 | ABBVIE INC. | VRAYLAR (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,250.00 | General |
| Category: NEUROSCIENCE | ||||||
| 07/29/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $9.07 | General |
| Category: NEUROSCIENCE | ||||||
| 07/15/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.86 | General |
| Category: NEUROSCIENCE | ||||||
| 07/08/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $9.43 | General |
| Category: NEUROSCIENCE | ||||||
| 06/26/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $18.02 | General |
| Category: Neuropsychiatry | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 603 | 2,008 | $621,849 | $146,205 |
| 2022 | 12 | 797 | 2,895 | $779,640 | $211,408 |
| 2021 | 10 | 884 | 3,290 | $925,820 | $253,794 |
| 2020 | 11 | 1,101 | 3,851 | $703,347 | $266,891 |
Total Patients
3,385
Total Services
12,044
Medicare Billing
$878,297
Procedure Codes
41
All Medicare Procedures & Services
41 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 172 | 1,061 | $159,150 | $60,868 | 38.2% |
| 90868 | Treatment using magnetic field to stimulate nerve cells in brain, subsequent delivery and management | Office | 2023 | 13 | 286 | $311,740 | $40,252 | 12.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 149 | 165 | $57,750 | $18,908 | 32.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 110 | 259 | $40,080 | $12,887 | 32.2% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 124 | 138 | $20,700 | $8,127 | 39.3% |
| 90837 | Psychotherapy, 1 hour | Office | 2023 | 13 | 55 | $12,079 | $3,555 | 29.4% |
| 90867 | Treatment using magnetic field to stimulate nerve cells in brain, initial delivery and management | Office | 2023 | 11 | 11 | $18,700 | $1,417 | 7.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 11 | 33 | $1,650 | $191.16 | 11.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 196 | 1,470 | $220,500 | $78,148 | 35.4% |
| 90868 | Treatment using magnetic field to stimulate nerve cells in brain, subsequent delivery and management | Office | 2022 | 12 | 276 | $300,840 | $38,868 | 12.9% |
| 90837 | Psychotherapy, 1 hour | Office | 2022 | 39 | 307 | $69,075 | $30,622 | 44.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 187 | 204 | $71,400 | $28,796 | 40.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 139 | 345 | $52,800 | $17,672 | 33.5% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 146 | 162 | $24,300 | $8,630 | 35.5% |
| 90867 | Treatment using magnetic field to stimulate nerve cells in brain, initial delivery and management | Office | 2022 | 11 | 13 | $22,100 | $1,995 | 9.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 19 | 23 | $5,530 | $1,889 | 34.2% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 13 | 15 | $3,000 | $1,590 | 53.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 11 | 11 | $3,850 | $1,526 | 39.6% |
| 90791 | Psychiatric diagnostic evaluation | Office | 2022 | 13 | 13 | $3,445 | $1,094 | 31.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 11 | 56 | $2,800 | $577.96 | 20.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 233 | 1,583 | $237,450 | $86,147 | 36.3% |
| 90868 | Transcranial magnetic stimulation treatment (stimulates nerve cells in brain to improve symptoms of depression), subsequent delivery and management, per session | Office | 2021 | 21 | 422 | $406,850 | $56,920 | 14.0% |
| 90837 | Psychotherapy, 60 minutes | Office | 2021 | 45 | 405 | $83,575 | $43,392 | 51.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 197 | 211 | $73,850 | $30,122 | 40.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 166 | 385 | $59,100 | $21,068 | 35.6% |
About Dr. Keshavpal Reddy, M.D
Dr. Keshavpal Reddy, M.D is a Addiction Medicine healthcare provider based in Greensboro, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1942269766.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Keshavpal Reddy, M.D has received a total of $596,383 in payments from pharmaceutical and medical device companies, with $29,560 received in 2024. These payments were reported across 1,145 transactions from 35 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($529,618).
As a Medicare-enrolled provider, Reddy has provided services to 3,385 Medicare beneficiaries, totaling 12,044 services with total Medicare billing of $878,297. Data is available for 4 years (2020–2023), covering 41 distinct procedure/service records.
Ad
Practice Information
- Specialty Addiction Medicine
- Other Specialties Psychiatry
- Location Greensboro, NC
- Active Since 03/21/2006
- Last Updated 04/13/2023
- Taxonomy Code 2084A0401X
- Entity Type Individual
- NPI Number 1942269766
Products in Payments
- VRAYLAR (Drug) $457,737
- ARISTADA (Drug) $59,389
- REXULTI (Drug) $42,581
- Dyanavel XR (Drug) $8,629
- FANAPT (Drug) $7,327
- Aristada 441 mg (Drug) $5,767
- Quillichew ER (Drug) $4,775
- Quillivant (Drug) $3,042
- CAPLYTA (Drug) $1,340
- SUNOSI (Drug) $800.00
- LATUDA (Drug) $666.24
- INGREZZA (Drug) $634.02
- ABILIFY MAINTENA (Drug) $523.31
- Equetro (Drug) $320.05
- Lucemyra/Lofexidine (Drug) $231.41
- LYBALVI (Drug) $211.24
- VIIBRYD (Drug) $202.64
- Dayvigo (Drug) $151.09
- Vivitrol (Drug) $130.01
- NUPLAZID (Drug) $129.05
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.